Literature DB >> 7560172

Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis.

P Aitola1, A Miettinen, A Mattila, M Matikainen, E Soppi.   

Abstract

AIMS: To study the effect of proctocolectomy on the antineutrophil cytoplasmic antibody (ANCA) titres in association with ulcerative colitis.
METHODS: Serum samples were taken from 15 patients with ulcerative colitis immediately before and at a mean of 24 months after proctocolectomy. Indirect immunofluorescence for ANCA and enzyme immunoassays for myeloperoxidase and proteinase-3 antibodies were employed. A liver biopsy was taken from every patient during the proctocolectomy, and serum liver enzyme activities were also determined.
RESULTS: Before proctocolectomy, 13 of the 15 patients had perinuclear antineutrophil cytoplasmic antibodies (p-ANCA). Additionally, one patient had a low tire of classical cytoplasmic ANCA and one had granulocyte specific antinuclear antibodies. After proctocolectomy, the ANCA titres decreased in 10 patients, in two of whom they became negative. The titres remained the same in four patients with positive ANCA and increased twofold in one patient. Only one patient was proteinase-3 antibody positive and all 15 patients were myeloperoxidase antibody negative. The clinical condition improved in all patients, irrespective of the ANCA status after proctocolectomy. Seven patients, all of whom were positive for p-ANCA before proctocolectomy, had histological liver abnormalities. No correlation was observed between serum liver enzyme levels and ANCA staining patterns or titres.
CONCLUSIONS: Proctocolectomy decreased the ANCA titres in the majority of our patients, suggesting that reduction of the inflammation or the available antigenic material modifies the immune disturbance related to ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7560172      PMCID: PMC502716          DOI: 10.1136/jcp.48.7.645

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  19 in total

1.  A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease.

Authors:  A Saxon; F Shanahan; C Landers; T Ganz; S Targan
Journal:  J Allergy Clin Immunol       Date:  1990-08       Impact factor: 10.793

2.  Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis.

Authors:  R H Duerr; S R Targan; C J Landers; N F LaRusso; K L Lindsay; R H Wiesner; F Shanahan
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

3.  Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses.

Authors:  R H Duerr; S R Targan; C J Landers; L R Sutherland; F Shanahan
Journal:  Gastroenterology       Date:  1991-06       Impact factor: 22.682

4.  Clinical significance of autoantibodies against neutrophil cytoplasmic components in patients with renal disease.

Authors:  J Mustonen; E Soppi; A Pasternack; O Hällström
Journal:  Am J Nephrol       Date:  1990       Impact factor: 3.754

5.  Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis.

Authors:  J Ludwig; S S Barham; N F LaRusso; L R Elveback; R H Wiesner; J T McCall
Journal:  Hepatology       Date:  1981 Nov-Dec       Impact factor: 17.425

6.  A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease.

Authors:  J A Rump; J Schölmerich; V Gross; M Roth; R Helfesrieder; A Rautmann; J Lüdemann; W L Gross; H H Peter
Journal:  Immunobiology       Date:  1990-11       Impact factor: 3.144

7.  Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis.

Authors:  R Olsson; A Danielsson; G Järnerot; E Lindström; L Lööf; P Rolny; B O Rydén; C Tysk; S Wallerstedt
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

8.  Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.

Authors:  F J van der Woude; N Rasmussen; S Lobatto; A Wiik; H Permin; L A van Es; M van der Giessen; G K van der Hem; T H The
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

Review 9.  Antineutrophil cytoplasmic autoantibodies and associated diseases: a review.

Authors:  J C Jennette; R J Falk
Journal:  Am J Kidney Dis       Date:  1990-06       Impact factor: 8.860

10.  Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre.

Authors:  J W Tervaert; M G Huitema; R J Hené; W J Sluiter; T H The; G K van der Hem; C G Kallenberg
Journal:  Lancet       Date:  1990-09-22       Impact factor: 79.321

View more
  4 in total

1.  Diagnostic value of classical and atypical antineutrophil cytoplasmic antibody (ANCA) immunofluorescence patterns.

Authors:  R C Wong; R A Silvestrini; J A Savige; D A Fulcher; E M Benson
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

Review 2.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis.

Authors:  P R Fleshner; E A Vasiliauskas; L Y Kam; N E Fleshner; J Gaiennie; M T Abreu-Martin; S R Targan
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

4.  Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis.

Authors:  Gil Y Melmed; Phillip R Fleshner; Ovunc Bardakcioglu; Andrew Ippoliti; Eric A Vasiliauskas; Konstantinos A Papadakis; Marla Dubinsky; Carol Landers; Jerome I Rotter; Stephan R Targan
Journal:  Dis Colon Rectum       Date:  2007-12-18       Impact factor: 4.585

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.